Liu Jiahui, Wei Xiunan, Wang Tong, Zhang Miaomiao, Gao Ying, Cheng Yan, Chi Lili
College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
College of Nursing, Shandong University of Traditional Chinese Medicine, Jinan, China.
Front Pharmacol. 2024 Feb 26;15:1372766. doi: 10.3389/fphar.2024.1372766. eCollection 2024.
Cardiovascular disease (CVD) is a serious public health problem, and among non-communicable diseases, CVD is now the leading cause of mortality and morbidity worldwide. CVD involves multiple organs throughout the body, especially the intestinal tract is the first to be involved. The impairment of the intestinal mucosal barrier is considered a significant pathological alteration in CVD and also contributes to the accelerated progression of the disease, thereby offering novel insights for CVD prevention and treatment. The treatment of Chinese medicine is characterized by multi-metabolites, multi-pathways, and multi-targets. In recent years, the studies of Traditional Chinese Medicine (TCM) in treating CVD by repairing the intestinal mucosal barrier have gradually increased, showing great therapeutic potential. This review summarizes the studies related to the treatment of CVD by TCM (metabolites of Chinese botanical drugs, TCM formulas, and Chinese patent medicine) targeting the repair of the intestinal mucosal barrier, as well as the potential mechanisms. We have observed that TCM exerts regulatory effects on the structure and metabolites of gut microbiota, enhances intestinal tight junctions, improves intestinal dyskinesia, repairs intestinal tissue morphology, and preserves the integrity of the intestinal vascular barrier through its anti-inflammatory, antioxidant, and anti-apoptotic properties. These multifaceted attributes position TCM as a pivotal modulator of inhibiting myocardial fibrosis, and hypertrophy, and promoting vascular repairment. Moreover, there exists a close association between cardiovascular risk factors such as hyperlipidemia, obesity, and diabetes mellitus with CVD. We also explore the mechanisms through which Chinese botanical drugs impact the intestinal mucosal barrier and regulate glucose and lipid metabolism. Consequently, these findings present novel insights and methodologies for treating CVD.
心血管疾病(CVD)是一个严重的公共卫生问题,在非传染性疾病中,CVD现已成为全球范围内导致死亡和发病的主要原因。CVD累及全身多个器官,尤其是肠道是最先受累的器官。肠道黏膜屏障的损害被认为是CVD的一种重要病理改变,也促使疾病加速进展,从而为CVD的预防和治疗提供了新的见解。中药治疗具有多代谢产物、多途径、多靶点的特点。近年来,中医药通过修复肠道黏膜屏障治疗CVD的研究逐渐增多,显示出巨大的治疗潜力。本综述总结了中医药(植物药代谢产物、中药方剂和中成药)靶向修复肠道黏膜屏障治疗CVD的相关研究及其潜在机制。我们观察到,中药通过其抗炎、抗氧化和抗凋亡特性,对肠道微生物群的结构和代谢产物发挥调节作用,增强肠道紧密连接,改善肠道运动障碍,修复肠道组织形态,并维持肠道血管屏障的完整性。这些多方面的特性使中药成为抑制心肌纤维化和肥大以及促进血管修复的关键调节因子。此外,高脂血症、肥胖症和糖尿病等心血管危险因素与CVD之间存在密切关联。我们还探讨了植物药影响肠道黏膜屏障并调节糖脂代谢的机制。因此,这些发现为治疗CVD提供了新的见解和方法。